Identification and validation of Kallikrein-ralated peptidase 11 as a novel prognostic marker of gastric cancer based on immunohistochemistry

Journal of Surgical Oncology

Volumn 104, Issue 5, 2011, Pages 516-524

  Wen, Yu Gang ^a   Wang, Quan ^a   Zhou, Chong Zhi ^a   Yan, Dong Wang ^a   Qiu, Guo Qiang ^a   Yang, Chun ^b   Tang, Hua Mei ^a   Peng, Zhi Hai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

differentially expressed gene; gastric carcinoma; Kallikrein related peptidase 11; microarray; prognosis

Indexed keywords

COMPLEMENTARY DNA; KALLIKREIN RELATED PEPTIDASE 11; PEPTIDASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CANCER RISK; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GASTRECTOMY; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STOMACH CANCER; STOMACH MUCOSA;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE ENDOPEPTIDASES; STOMACH; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80052474106     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21981     Document Type: Article

References (44)

1. Leung WK, Wu MS, Kakugawa Y, et al.: Screening for gastric cancer in Asia: Current evidence and practice. Lancet Oncol 2008; 9: 279-287. (Pubitemid 351722947)
2. Cunningham D, Oliveira J,: Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19: ii23-ii24.
3. Wang X, Wu CX, Zheng Y, et al.: Time trends and characteristics of gastric cancer incidence in urban Shanghai. Zhonghua Liu Xing Bing Xue Za Zhi 2007; 28: 875-880.
4. Fan JW, Peng ZH, Zhou CZ, et al.: Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genome-wide gene-expression analyses: Identification and validation of IFITM3 as biomarker of colon carcinogenesis. Cancer 2008; 113: 266-275.
5. Gilks CB, Vanderhyden BC, Zhu S, et al.: Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005; 96: 684-694. (Pubitemid 40255487)
6. Pan YL, Zhao LN, Liu ZG, et al.: KCNE2, a down-regulated gene identified by in silico analysis, suppressed proliferation of gastric cancer cells. Cancer Lett 2007; 246: 129-138.
7. Zhang X, Yang JJ, Kim YS, et al.: An 8-gene signature, including methylated and down-regulated glutathione peroxidase 3, of gastric cancer. Int J Oncol 2010; 36: 405-414.
8. Kim M, Rha SY,: Prognostic index reflecting genetic alteration related to disease-free time for gastric cancer patient. Oncol Rep 2009; 22: 421-431.
9. Jee CD, Kim MA, Jung EJ, et al.: Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur J Cancer 2009; 45: 1282-1293.
10. Murohashi M, Hinohara K, Kuroda M, et al.: Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. Br J Cancer 2010; 102: 206-212.
11. Subramanian A, Tamayo P, Mootha VK, et al.: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550. (Pubitemid 41528093)
12. Anders CK, Hsu DS, Broadwater G, et al.: Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008; 26: 3324-3330.
13. UICC, Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. 6th edition. NewYork: Wiley-Liss; 2002.
14. Li DW, Yan DW, Tang HM, et al.: IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol 2009; 16: 3499-3506.
15. Borgono CA, Diamandis EP,: The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-890. (Pubitemid 39472954)
16. Yamada Y, Arao T, Gotoda T, et al.: Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci 2008; 99: 2193-2199.
17. Yang S, Jeung HC, Jeong HJ, et al.: Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. Genomics 2007; 89: 451-459. (Pubitemid 46413666)
18. Elliott MB, Irwin DM, Diamandis EP,: In silico identification and Bayesian phylogenetic analysis of multiple new mammalian kallikrein gene families. Genomics 2006; 88: 591-599. (Pubitemid 44512074)
19. Obiezu CV, Diamandis EP,: Human tissue kallikrein gene family: Applications in cancer. Cancer Lett 2005; 224: 1-22. (Pubitemid 40720363)
20. Planque C, Ainciburu M, Heuze-Vourc'h N, et al.: Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues. Biol Chem 2006; 387: 783-788. (Pubitemid 43964801)
21. Petraki CD, Gregorakis AK, Vaslamatzis MM, et al.: Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10, and 11 in renal cell carcinoma. Tumor Biol 2006; 27: 1-7. (Pubitemid 41832698)
22. Paliouras M, Borgono C, Diamandis EP,: Human tissue kallikreins: The cancer biomarker family. Cancer Lett 2007; 249: 61-79. (Pubitemid 46427999)
23. Talieri M, Li L, Zheng Y, et al.: The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer 2009; 100: 1659-1665.
24. Sano A, Sangai T, Maeda H, et al.: Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. Int J Oncol 2007; 30: 1493-1498.
25. Stavropoulou P, Gregorakis AK, Plebani M, et al.: Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta 2005; 357: 190-195. (Pubitemid 40884600)
26. Planque C, Li L, Zheng YY, et al.: A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res 2008; 14: 1355-1362. (Pubitemid 351413915)
27. Thomadaki H, Mavridis K, Talieri M, et al.: Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thromb Haemost 2009; 101: 373-380.
28. Scorilas A, Gregorakis AK,: mRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy. Biol Chem 2006; 387: 789-793. (Pubitemid 43964802)
29. Bayani J, Marrano P, Graham C, et al.: Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas. Mol Oncol 2011; 5: 48-60.
30. Inoue Y, Yokobori T, Yokoe T, et al.: Clinical significance of human kallikrein7 gene expression in colorectal cancer. Ann Surg Oncol 2010; 17: 3037-3042.
31. White NM, Bui A, Mejia-Guerrero S, et al.: Dysregulation of kallikrein-related peptidases in renal cell carcinoma: Potential targets of miRNAs. Biol Chem 2010; 391: 411-423.
32. Borgono CA, Fracchioli S, Yousef GM, et al.: Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int J Cancer 2003; 106: 605-610. (Pubitemid 36966221)
33. Yousef GM, Polymeris ME, Yacoub GM, et al.: Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003; 63: 2223-2227. (Pubitemid 36538630)
34. Shigemasa K, Gu LJ, Tanimoto H, et al.: Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer. Clin Cancer Res 2004; 10: 2766-2770. (Pubitemid 38509153)
35. Mitsui S, Nakamura T, Okui A, et al.: Multiple promoters regulate tissue-specific alternative splicing of the human kallikrein gene, KLK11/hippostasin. FEBS J 2006; 273: 3678-3686. (Pubitemid 44166649)
36. Yoon H, Blaber SI, Evans DM, et al.: Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis. Protein Sci 2008; 17: 1998-2007.
37. Paliouras M, Diamandis EP,: Intracellular signaling pathways regulate hormone-dependent kallikrein gene expression. Tumour Biol 2008; 29: 63-75.
38. Gabison EE, Mourah S, Steinfels E,: Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas. Am J Pathol 2005; 166: 209-219.
39. Bi XC, He HC, Ye YK, et al.: Association of TMPRSS2 and KLK11 gene expression levels with clinical progression of human prostate cancer. Med Oncol 2010; 27: 145-151.
40. Dorn J, Harbeck N, Kates R, et al.: Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann Oncol 2011; 22: 877-883.
41. Goettig P, Magdolen V, Brandstetter H,: Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie 2010; 92: 1546-1567.
42. Beaufort N, Plaza K, Utzschneider D, et al.: Interdependence of kallikrein-related peptidases in proteolytic networks. Biol Chem 2010; 391: 581-587.
43. Schmitt M, Magdolen V,: Using kallikrein-related peptidases (KLK) as novel cancer biomarkers. Thromb Haemost 2009; 101: 222-224.
44. Sotiropoulou G, Pampalakis G, Diamandis EP,: Functional roles of human kallikrein-related peptidases. J Biol Chem 2009; 284: 32989-32994.